Revenue of approximately $34.9 million for the three months ended December 31, 2024, representing 11% year-over-year growth.
Instruments revenue of approximately $3.1 million, representing a 6% year-over-year decline.
Consumables revenue of approximately $17.4 million, remaining flat year-over-year.
Accelerator revenue of approximately $8.6 million, representing 22% year-over-year growth. As previously disclosed, the fourth quarter performance does not include $1.5 million of revenue from an order under an agreement with Eli Lilly, which was completed in the third quarter of 2024.
Other revenue of approximately $5.8 million, representing 57% year-over-year growth.
The Company used approximately $4.4 million of cash in the quarter ended December 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.